# PharmAgents: Building a Virtual Pharma with Large Language Model Agents

arXiv: https://arxiv.org/abs/2503.22164 · HTML: https://mlsanity.com/paper/2503.22164/

## Key facts

- Cited by 21 papers in the map (data through 14 Oct 2026).
- Placed in Medical and scientific domain agents, one of 16 directions in LLM agents and tool use.
- Builds on 17 of its 57 references that are in the map.
- First posted on arXiv 28 Mar 2025.

## Placed in

- LLM agents and tool use / [Medical and scientific domain agents](https://mlsanity.com/agents/medical-and-scientific-domain-agents/)

## Builds on (most cited first, 17 of 17)

- [GPT-4 Technical Report](https://mlsanity.com/paper/2303.08774/) (2023)
- [DeepSeek-R1: Incentivizing Reasoning Capability in LLMs via Reinforcement Learning](https://mlsanity.com/paper/2501.12948/) (2025)
- [MetaGPT: Meta Programming for A Multi-Agent Collaborative Framework](https://mlsanity.com/paper/2308.00352/) (2023)
- [Agent Hospital: A Simulacrum of Hospital with Evolvable Medical Agents](https://mlsanity.com/paper/2405.02957/) (2024)
- [Pocket2Mol: Efficient Molecular Sampling Based on 3D Protein Pockets](https://mlsanity.com/paper/2205.07249/) (2022)
- [3D Equivariant Diffusion for Target-Aware Molecule Generation and Affinity Prediction](https://mlsanity.com/paper/2303.03543/) (2023)
- [DeepDTA: Deep Drug-Target Binding Affinity Prediction](https://mlsanity.com/paper/1801.10193/) (2018)
- [Editable Scene Simulation for Autonomous Driving via Collaborative LLM-Agents](https://mlsanity.com/paper/2402.05746/) (2024)
- [DecompDiff: Diffusion Models with Decomposed Priors for Structure-Based Drug Design](https://mlsanity.com/paper/2403.07902/) (2024)
- [MolCRAFT: Structure-Based Drug Design in Continuous Parameter Space](https://mlsanity.com/paper/2404.12141/) (2024)
- [Can Large Language Models Empower Molecular Property Prediction?](https://mlsanity.com/paper/2307.07443/) (2023)
- [ChemAgent: Self-updating Library in Large Language Models Improves Chemical Reasoning](https://mlsanity.com/paper/2501.06590/) (2025)
- [Improved Protein-ligand Binding Affinity Prediction with Structure-Based Deep Fusion Inference](https://mlsanity.com/paper/2005.07704/) (2020)
- [DrugCLIP: Contrastive Protein-Molecule Representation Learning for Virtual Screening](https://mlsanity.com/paper/2310.06367/) (2023)
- [MolecularGPT: Open Large Language Model (LLM) for Few-Shot Molecular Property Prediction](https://mlsanity.com/paper/2406.12950/) (2024)
- [UAlign: Pushing the Limit of Template-free Retrosynthesis Prediction with Unsupervised SMILES Alignment](https://mlsanity.com/paper/2404.00044/) (2024)
- [S-MolSearch: 3D Semi-supervised Contrastive Learning for Bioactive Molecule Search](https://mlsanity.com/paper/2409.07462/) (2024)

## Built on by (most cited first, 21 of 21)

- [From AI for Science to Agentic Science: A Survey on Autonomous Scientific Discovery](https://mlsanity.com/paper/2508.14111/) (2025)
- [A Survey of Agentic Reasoning for Large Language Models: Towards Recursively Self-Improving and Collective Agents](https://mlsanity.com/paper/2601.12538/) (2026)
- [El Agente: An Autonomous Agent for Quantum Chemistry](https://mlsanity.com/paper/2505.02484/) (2025)
- [LLM-based Agentic Reasoning Frameworks: A Survey from Methods to Scenarios](https://mlsanity.com/paper/2508.17692/) (2025)
- [Autonomous Agents for Scientific Discovery: Orchestrating Scientists, Language, Code, and Physics](https://mlsanity.com/paper/2510.09901/) (2025)
- [MedSentry: Understanding and Mitigating Safety Risks in Medical LLM Multi-Agent Systems](https://mlsanity.com/paper/2505.20824/) (2025)
- [Mozi: Governed Autonomy for Drug Discovery LLM Agents](https://mlsanity.com/paper/2603.03655/) (2026)
- [Camyla: Scaling Autonomous Research in Medical Image Segmentation](https://mlsanity.com/paper/2604.10696/) (2026)
- [FROGENT: An End-to-End Full-process Drug Design Multi-Agent System](https://mlsanity.com/paper/2508.10760/) (2025)
- [MolLingo: Molecule-Native Representations for LLM-Powered Scientific Agents](https://mlsanity.com/paper/2605.27853/) (2026)
- [Exploring Modularity of Agentic Systems for Drug Discovery](https://mlsanity.com/paper/2506.22189/) (2025)
- [An Auditable Agent Platform For Automated Molecular Optimisation](https://mlsanity.com/paper/2508.03444/) (2025)
- [PeroMAS: A Multi-agent System of Perovskite Material Discovery](https://mlsanity.com/paper/2602.13312/) (2026)
- [Agentic AI in Healthcare & Medicine: A Seven-Dimensional Taxonomy for Empirical Evaluation of LLM-based Agents](https://mlsanity.com/paper/2602.04813/) (2026)
- [Biomedical reasoning in action: Multi-agent System for Auditable Biomedical Evidence Synthesis](https://mlsanity.com/paper/2510.05335/) (2025)
- [DiscoVerse: Multi-Agent Pharmaceutical Co-Scientist for Traceable Drug Discovery and Reverse Translation](https://mlsanity.com/paper/2511.18259/) (2025)
- [Deciphering Scientific Reasoning Steps from Outcome Data for Molecule Optimization](https://mlsanity.com/paper/2603.20262/) (2026)
- [Agents in the Wild: Where Research Meets Deployment](https://mlsanity.com/paper/2607.19336/) (2026)
- [Evaluating Agentic Bioinformatics through Function, Evidence, and Validation](https://mlsanity.com/paper/2607.27556/) (2026)
- [DrugReason: Dynamic Multi-View Reasoning over Knowledge Graph and Language Evidence for Drug Repurposing](https://mlsanity.com/paper/2609.06779/) (2026)
- [M3OS: A Monte Carlo Graph Search-Orchestrated Multi-Agent LLM System for Evidence-Traced Molecular Optimization](https://mlsanity.com/paper/2609.34491/) (2026)

## Abstract (arXiv)

The discovery of novel small molecule drugs remains a critical scientific challenge with far-reaching implications for treating diseases and advancing human health. Traditional drug development--especially for small molecule therapeutics--is a highly complex, resource-intensive, and time-consuming process that requires multidisciplinary collaboration. Recent breakthroughs in artificial intelligence (AI), particularly the rise of large language models (LLMs), present a transformative opportunity to streamline and accelerate this process. In this paper, we introduce PharmAgents, a virtual pharmaceutical ecosystem driven by LLM-based multi-agent collaboration. PharmAgents simulates the full drug discovery workflow--from target discovery to preclinical evaluation--by integrating explainable, LLM-driven agents equipped with specialized machine learning models and computational tools. Through structured knowledge exchange and automated optimization, PharmAgents identifies potential therapeutic targets, discovers promising lead compounds, enhances binding affinity and key molecular properties, and performs in silico analyses of toxicity and synthetic feasibility. Additionally, the system supports interpretability, agent interaction, and self-evolvement, enabling it to refine future drug designs based on prior experience. By showcasing the potential of LLM-powered multi-agent systems in drug discovery, this work establishes a new paradigm for autonomous, explainable, and scalable pharmaceutical research, with future extensions toward comprehensive drug lifecycle management.